The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study

Journal of Human Hypertension

Volumn 20, Issue 6, 2006, Pages 460-464

  Olsen, M H ^a   Wachtell, K ^a   Dahlof B ^b   Devereux, R B ^c   Ibsen, H ^a   Kjeldsen, S E ^d   Lindholm, L H ^e   Lyle, P A ^f   Nieminen, M S ^g  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UMEÅ UNIVERSITY   (Sweden)

^f MERCK RESEARCH LABORATORIES   (United States)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; LOSARTAN;

ALBUMINURIA; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY RECANALIZATION; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; PERIPHERAL VASCULAR DISEASE; REGRESSION ANALYSIS; REVASCULARIZATION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; MIDDLE AGED; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646830137     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002013     Document Type: Article

References (14)

1. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de FU et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359(9311): 995-1003.
2. Olsen MH, Wachtell K, Neland K, Bella JN, Rokkedal J, ge-Petersen H et al. Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14(3): 177-183.
3. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW et al. Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100(11): 1223-1229.
4. Schiffrin EL. Beyond blood pressure: The endothelium and atherosclerosis progression. Am J Hypertens 2002; 15(10 Part 2): 115S-122S.
5. Dahlof B, Devereux RB, Julius S, Kjeldsen SE, Beevers G, de Faire U et al. Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint Reduction in Hypertension. Hypertension 1998; 32(6): 989-997.
6. Olsen MH, Fossum E, Hoieggen A, Wachtell K, Hjerkinn E, Nesbitt SD et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 2005; 23(4): 891-898.
7. Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101(13): 1586-1593.
8. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
9. Moutsatsos GD. More hype than HOPE. Hypertension 2003; 41(4): E4.
10. Herbertsson P, Fagher B. Effects of verapamil and atenolol on exercise tolerance in 5,000 m cross-country running: A double-blind cross-over study in normal humans. J Cardiovasc Pharmacol 1990; 16(1): 23-27.
11. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19): 2570-2581.
12. Jensen JS. Renal and systemic transvascular albumin leakage in severe atherosclerosis. Arterioscler Thromb Vasc Biol 1995; 15(9): 1324-1329.
13. Devereux RB, Dahlof B, Gerdts E, Boman K, Nieminen MS, Papademetriou V et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: The Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation 2004; 110(11): 1456-1462.
14. Devereux RB, Roman MJ, Palmieri V, Okin PM, Boman K, Gerdts E et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: The LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens 2000; 18(8): 1129-1138.